Home › Liver Cancer (Hepatocellular Carcinoma) › NCT05488522
SBRT With Atezo/Bev for HCC
RecruitingPhase 1
A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated. Exclusion Criteria: \-
About the study
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
What is being tested
- SBRT + atezolizumab and bevacizumab (biological)
Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 18 · Started: Sep 1, 2022
Contact the study team
- Edgar Ben-Josef, MD · Phone: 215-615-6767
Official record on ClinicalTrials.gov — NCT05488522
Locations in the U.S.
| Pennsylvania | Abramson Cancer Center of the University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.